Active	Status	Sponsor type	Region	Phase	Filter
24 Active 10 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kim, Jung Eun
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma	Recruiting	3	200	Europe, US, RoW	Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice	TransThera Sciences (Nanjing), Inc.	Cholangiocarcinoma	05/26	08/26
NCT04434482: IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Completed	1/2	59	US, RoW	IMP4297(senaparib), temozolomide	Impact Therapeutics, Inc.	Advanced Solid Tumours, Small Cell Lung Cancer	04/24	04/24
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN	Terminated	1	18	Europe, US, RoW	Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
Kim, Kyung-Oh
No trials found